Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Mirum Pharmaceuticals Inc (MIRM)

312 + Investors. Track Smart Money conviction in MIRM. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +21
Streak
8Q ▲
Buyers last Q
57%

Smart Money Signals — MIRM

Based on 330 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 8 quarters in a row

last 6Q
For 8 consecutive quarters, more hedge funds added MIRM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
330 hedge funds hold MIRM right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +54% more funds vs a year ago

fund count last 6Q
+116 new funds entered over the past year (+54% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 57% buying

193 buying147 selling
Last quarter: 193 funds bought or added vs 147 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~67 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 71 → 61 → 68 → 67. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
📌

Mixed — 39% long-term, 36% new

■ 39% conviction (2yr+) ■ 25% medium ■ 36% new
Of the 330 current holders: 130 (39%) held >2 years, 81 held 1–2 years, and 119 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💰

Value +32% but shares only +13% — price-driven

Value
+31%
Shares
+12%
Last quarter: the total dollar value of institutional holdings rose +32%, but actual share count only changed +13%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
➡️

Steady discovery — ~67 new funds/quarter

34 → 71 → 61 → 68 → 67 new funds/Q
New funds entering each quarter: 71 → 61 → 68 → 67. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 44% veterans vs 42% newcomers

■ 44% veterans ■ 13% 1-2yr ■ 42% new
Entry-cohort mix of 335 holders: 148 (44%) are 2+ year veterans, 45 entered 1–2 years ago, and 142 (42%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 36% AUM from major funds

36% from top-100 AUM funds
51 of 327 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.4
out of 10
Moderate Exit Risk
Exit risk score 4.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — MIRM

In 2026 Q2, 193 hedge funds were net buyers of MIRM (67 opened a new position, 126 added to an existing one), while 147 reduced or exited (101 trimmed, 46 sold completely) — a 57% buyer ratio, indicating a slight buying edge. This marks 8 consecutive quarters of net institutional buying — a persistent conviction signal. 36% of total institutional value in MIRM is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +21 funds (more new holders than closures). Total institutional holders: 330.

Hedge Fund Ownership: MIRM

How many hedge funds hold MIRM — quarterly history vs. share price
Quarterly hedge fund ownership of MIRM vs. share price

Market Analysis: MIRM

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: MIRM

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Mirum Pharmaceuticals Inc (MIRM) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much MIRM has moved relative to its sector benchmark (XLV) since the 2026 Q3 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End September 30, 2026 · 50d ago
MIRM
+8.2%
XLV
+5.4%

MIRM outperformed XLV by +2.8% since September 30, 2026.

Since 13F Filing Date November 14, 2026 · 5d ago
MIRM
-1.6%
XLV
-6.0%

Since the filing became public, MIRM outperformed XLV by +4.4% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Growing Institutional Interest

Quality funds are building positions — conviction is rising but not yet widespread.

14 top-rated funds 6 high-conviction
Consensus
5.1
/ 10
breadth
×
Elite
6.6
/ 10
conviction
Hedge Fund Positioning: MIRM
312 + Investors

Track Smart Money conviction in MIRM. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q3) Prior (2026 Q2) Change
Funds Holding 312 330 -5.45%
13F Shares 72M 77M -5.97%
Total Value $5.88B $7.93B -25.76%
New Positions 48 67 -19
Increased Positions 126 125 +1
Closed Positions 65 46 +19
Reduced Positions 95 100 -5
Total Calls 5 4 25.0%
Total Puts 4 4 -
PUT/CALL Ratio 0.8 1.0 Neutral

Statistics: MIRM

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q3)

312 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MIRM. Verified SEC 13F-HR filings.

QUARTER:
Top 25 MIRM holders by conviction (% of portfolio weight) — 2026 Q3 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Frazier Life Sciences Management, L.P. 16.29% 7,679,684 $656.5M
2 Boone Capital Management LLC 9.43% 415,641 $35.5M
3 Novo Holdings A/S 6.46% 1,125,000 $96.2M
4 Palo Alto Investors LP 4.93% 387,314 $33.1M
5 Tang Capital Management LLC 4.86% 1,236,027 $105.7M
6 Highlander Partners, L.P. 3.73% 122,980 $10.5M
7 Rock Springs Capital Management LP 3.58% 779,790 $66.7M
8 Patient Square Capital LP 3.19% 234,000 $20.0M
9 TCG Crossover Management, LLC 2.70% 1,118,967 $95.6M
10 Stonepine Capital Management, LLC 2.64% 40,000 $4.2M
11 Octagon Capital Advisors LP 1.93% 169,450 $14.5M
12 NAN FUNG TRINITY (HK) Ltd 1.83% 222,679 $19.0M
13 Penn Capital Management Company, LLC 1.78% 286,281 $24.5M
14 Next Century Growth Investors LLC 1.70% 311,609 $26.6M
15 Atle Fund Management AB 1.60% 70,071 $6.0M
16 Eventide Asset Management, LLC 1.49% 1,248,259 $106.7M
17 Ground Swell Capital, LLC 1.30% 6,599 $564K
18 Essex Investment Management Co LLC 1.29% 101,716 $8.7M
19 Bvf Inc/Il 1.15% 407,226 $34.8M
20 Emerald Advisers, LLC 1.10% 469,771 $40.2M
21 Emerald Mutual Fund Advisers Trust 0.98% 281,185 $24.0M
22 Rhenman & Partners Asset Management AB 0.87% 91,855 $7.9M
23 HighVista Strategies LLC 0.60% 26,660 $2.3M
24 Secure Asset Management, LLC 0.59% 52,246 $4.5M
25 TimesSquare Capital Management, LLC 0.51% 364,782 $31.2M
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Stocks with similar institutional ownership

GTM 314 holdersHCI 314 holdersGBDC 314 holdersROG 313 holdersXMTR 313 holdersMBC 313 holdersFIW 313 holdersTRN 313 holdersSRPT 312 holdersGTY 312 holdersIAUM 312 holdersCPA 312 holders All stocks →

Frequently Asked Questions — Mirum Pharmaceuticals Inc (MIRM)

What does the Smart Money Trend signal show for MIRM?

Buying streak — 8 quarters in a row: For 8 consecutive quarters, more hedge funds added MIRM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for MIRM?

Slight buying edge — 57% buying: Last quarter: 193 funds bought or added vs 147 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for MIRM holders?

Strong quality — 36% AUM from major funds: 51 of 327 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held MIRM?

Mixed — 39% long-term, 36% new: Of the 330 current holders: 130 (39%) held >2 years, 81 held 1–2 years, and 119 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Mirum Pharmaceuticals Inc (MIRM) following the 2026 Q3 hedge fund 13F filings?

As of today, MIRM has moved -1.6% since the 2026 Q3 13F filing date (November 14, 2026), compared to -6.0% for the XLV sector ETF — an outperformance of +4.4%. Since the quarter end (September 30, 2026), MIRM has gained +8.2% vs +5.4% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →